Analyst IMS Investment Management Services Ltd. Raises Position in Eli Lilly and Company (NYSE:LLY)

Analyst IMS Investment Management Services Ltd. boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 69.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,986 shares of the company's stock after buying an additional 1,228 shares during the period. Analyst IMS Investment Management Services Ltd.'s holdings in Eli Lilly and Company were worth $2,466,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. LifeWealth Investments LLC increased its position in Eli Lilly and Company by 53.4% during the 1st quarter. LifeWealth Investments LLC now owns 704 shares of the company's stock worth $581,000 after purchasing an additional 245 shares during the period. Summa Corp. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $312,000. Marino Stram & Associates LLC boosted its stake in shares of Eli Lilly and Company by 34.5% in the first quarter. Marino Stram & Associates LLC now owns 3,842 shares of the company's stock valued at $3,173,000 after buying an additional 986 shares in the last quarter. PUREfi Wealth LLC boosted its stake in shares of Eli Lilly and Company by 82.3% in the first quarter. PUREfi Wealth LLC now owns 1,285 shares of the company's stock valued at $1,061,000 after buying an additional 580 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 5.7% during the first quarter. Kingswood Wealth Advisors LLC now owns 9,254 shares of the company's stock worth $7,591,000 after acquiring an additional 497 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $6.96 during trading on Thursday, reaching $784.28. The company had a trading volume of 2,441,727 shares, compared to its average volume of 3,656,357. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $743.29 billion, a PE ratio of 63.81, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a 50-day moving average price of $778.55 and a two-hundred day moving average price of $801.58.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.58 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.